Hongjuan Zheng1, Chenyang Ge2, Haiping Lin3, Lunpo Wu4,5, Qinghua Wang1, Shishi Zhou1, Wanfen Tang1, Xia Zhang1, Xiayun Jin1, Xifeng Xu1, Zhongwu Hong6, Jianfei Fu7, Jinlin Du8. 1. Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, China. 2. Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, China. 3. Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China. 4. Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. 5. Institute of Gastroenterology, Zhejiang University, Hangzhou, China. 6. Department of Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, Zhejiang Province, China. 7. Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, China. 11218276@zju.edu.cn. 8. Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, China. djl9090@163.com.
Abstract
BACKGROUND: The single progesterone receptor (PR)-positive phenotype (estrogen receptor (ER)-/PR + , sPR positive) is an infrequent and independent biological entity. However, the prognosis of patients with sPR-positive and her-2-negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them. METHODS: Patients during 2010-2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD). RESULTS: A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR-positive phenotype. The majority of sPR-positive breast cancer were basal-like subtype. Survival analysis showed that the sPR-positive breast cancer had similar prognosis comparing to double hormonal receptor-negative (ER-/PR-, dHoR-negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up. CONCLUSIONS: The patients with sPR-positive and her-2-negative breast cancer, similar to dHoR-negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR-positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.
BACKGROUND: The single progesterone receptor (PR)-positive phenotype (estrogen receptor (ER)-/PR + , sPR positive) is an infrequent and independent biological entity. However, the prognosis of patients with sPR-positive and her-2-negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them. METHODS: Patients during 2010-2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD). RESULTS: A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR-positive phenotype. The majority of sPR-positive breast cancer were basal-like subtype. Survival analysis showed that the sPR-positive breast cancer had similar prognosis comparing to double hormonal receptor-negative (ER-/PR-, dHoR-negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up. CONCLUSIONS: The patients with sPR-positive and her-2-negative breast cancer, similar to dHoR-negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR-positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.
Authors: Leen De Maeyer; Erik Van Limbergen; Katelijne De Nys; Philippe Moerman; Nathalie Pochet; Wouter Hendrickx; Hans Wildiers; Robert Paridaens; Ann Smeets; Marie-Rose Christiaens; Ignace Vergote; Karin Leunen; Frederic Amant; Patrick Neven Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: J L Ethier; A Ocaña; A Rodríguez Lescure; A Ruíz; E Alba; L Calvo; M Ruíz-Borrego; A Santaballa; C A Rodríguez; C Crespo; M Ramos; J Gracia Marco; A Lluch; I Álvarez; M Casas; M Sánchez-Aragó; E Carrasco; R Caballero; E Amir; M Martin Journal: Eur J Cancer Date: 2018-03-21 Impact factor: 9.162
Authors: Gábor Cserni; Monika Francz; Endre Kálmán; Gyöngyi Kelemen; Detre Csaba Komjáthy; Ilona Kovács; Janina Kulka; László Sarkadi; Nóra Udvarhelyi; László Vass; András Vörös Journal: Pathol Oncol Res Date: 2011-01-26 Impact factor: 3.201
Authors: P M Ravdin; S Green; T M Dorr; W L McGuire; C Fabian; R P Pugh; R D Carter; S E Rivkin; J R Borst; R J Belt Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: Valerie-Jeanne Bardou; Grazia Arpino; Richard M Elledge; C Kent Osborne; Gary M Clark Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544